

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Rozhon <i>et al.</i>	Confirmation No.:	9130
Serial No.:	09/712,033	Art Unit:	1651
Filed:	November 14, 2000	Examiner:	Irene Marx
For:	ENTERIC FORMULATIONS OF PROANTHOCYANIDIN POLYMER ANTIDIARRHEAL COMPOSITIONS	Attorney Docket No.:	11133-004-999

DECLARATION OF THE INVENTORS UNDER 37 C.F.R. § 1.131

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

We, Edward J. Rozhon, Atul S. Khandwala, Akram Sabouni, Gul P. Balwani, Jody Wai-Han Chan and David F. Sesin, citizens of the United States of America residing at 523 San Carlos Avenue, El Granada, California, 94018, 300 Winston Drive # 721, Cliffside Park, New Jersey 07010, 3398 Bing Hearst Drive, Suwanne, Georgia 30024, 6 Roberts Drive, Princeton, New Jersey 07010, 28065 Thorup Lane, Hayward, California 94542, and 557 Cambridge Drive, Benicia California 94510, respectively, do hereby declare and state that:

1. We are the inventors of the invention that is disclosed and claimed in the above-identified application, Serial No. 09/712,033 filed November 14, 2000, which claims priority to U.S. Application Serial No. 08/730,772 filed October 16, 1996, now abandoned. The claimed invention relates to methods for treating secretory diarrhea in animals by administering a pharmaceutical composition comprising an aqueous soluble proanthocyanidin polymer composition isolated from a Croton species or a Calophyllum species in which the

proanthocyanidin polymer composition is formulated to protect the proanthocyanidin polymer composition from the stomach environment, *e.g.*, coated with an enteric coating.

2. We are providing this Declaration to demonstrate that we conceived of and reduced to practice at least one embodiment of the claimed invention prior to August 16, 1996, which is the publication date of Davenport *et al.*, Pediatric Pulmonology, S13, Abstract 34.

3. Attached hereto as Exhibit 1 are copies of two pages from a Project Plan authored by co-inventor Edward J. Rozhon. We have reviewed Exhibit 1 and although the dates have been removed from this document, the date of this document is prior to August 16, 1996. Also, we confirm that the invention described in Exhibit 1 and all the acts relied upon in Exhibit 1 were carried out by one or more of us or at the direction of one or more of us in the United States of America prior to August 16, 1996. The pages set forth formulations of SP-303, which is an aqueous soluble proanthocyanidin polymer composition isolated from *Croton lechleri*, that protect SP-303 from acid, such as enteric coating and formulating with buffering or acid reducers.

4. Attached hereto as Exhibit 2 is a copy of Report No. SP-303-E-074 entitled "Effect of Enteric Coated SP-303 on Intestinal Fluid Accumulation in Cholera Toxin-treated Mice" ("the Report") authored by co-inventor Akram (Adam) Sabouni and Mei-Fong King, a laboratory technician acting under the direction of co-inventor Akram (Adam) Sabouni. We have reviewed Exhibit 2 and although the dates have been removed from this document, the date of this document is prior to August 16, 1996. Also, we confirm that the invention described in Exhibit 2 and all the acts relied upon in Exhibit 2 were carried out by one or more of us or at the direction of one or more of us in the United States of America prior to August 16, 1996. The Report summarizes the results of two experiments where enteric coated beads of SP-303 were orally administered to mice who had been given cholera toxin.

The experimental design is detailed on page 4 of 10 and page 5 of 10 of the Report. The mouse model used in these experiments to measure the effect a test compound, in this instance enteric coated SP-303, has on fluid accumulation in mice given cholera toxin is a well known and art-accepted *in vivo* model of the effect of the test compound on diarrhea in animals.

5. On pages 5 of 10 to 8 of 10 the Report, results of the two experiments are presented and discussed. In Experiment I, group C, which was treated with enteric coated beads of SP-303, showed significantly reduced ratios of fluid accumulation by an average of 32% and 29% as compared to control groups A and E, see Table 1 and Figure 1. In Experiment II, a single dose of enteric coated beads of SP-303 significantly reduced cholera toxin-induced fluid accumulation after a seven hour incubation with cholera toxin. Compared to control groups A and C, SP-303 enteric coated beads (group B) significantly reduced the ratios of fluid accumulation by an average of 45% and 38%, respectively, see Table 2 and Figure 2.

6. Attached hereto as Exhibit 3 are copies of notebook pages from laboratory notebook no. 333 of Mei-Fong King, a laboratory technician acting under the direction of co-inventor Akram (Adam) Sabouni. We have reviewed Exhibit 3 and although the dates have been removed from this document, the date of this document is prior to August 16, 1996. Also, we confirm that the invention described in Exhibit 3 and all the acts relied upon in Exhibit 3 were carried out by one or more of us or at the direction of one or more of us in the United States of America prior to August 16, 1996. The notebook pages set forth the raw data obtained from carrying out Experiment I discussed in the Report above.

7. Attached hereto as Exhibit 4 are copies of notebook pages from laboratory notebook no. 3368 of Mei-Fong King, a laboratory technician acting under the direction of co-inventor Akram (Adam) Sabouni. We have reviewed Exhibit 4 and although the dates

have been removed from this document, the date of this document is prior to August 16, 1996. Also, we confirm that the invention described in Exhibit 4 and all the acts relied upon in Exhibit 4 were carried out by one or more of us or at the direction of one or more of us in the United States of America prior to August 16, 1996. The notebook pages set forth the raw data obtained from carrying out Experiment II discussed in the Report above.

8. Exhibits 1 to 4 show that, prior to August 16, 1996, we had conceived and we, or persons acting under our direction, had reduced to practice the claimed methods by treating secretory diarrhea in an animal by orally administering a pharmaceutical composition comprising an enteric coated aqueous soluble proanthocyanidin polymer composition isolated from a Croton species or a Calophyllum species.

9. We declare further that all statements made in this Declaration of our own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: _____

Edward J. Rozhon

Date: _____

Atul S. Khandwala

Date: _____

Akram Sabouni

Date: _____


Gul P. Balwani

Date: _____

Jody Wai-Han Chan

Date: 02 Aug 06

David F. Sesin



PROVIR DEVELOPMENT STRATEGY

{Contingency Plan if SP-303/H₂O Inactive in CT Mouse Model}

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sep

Oct

Nov

Dec

SP-303/H₂O
CT/Mouse Model

- or ±

Development
of Acid Protection
Formulation

Toxicology?

Human Safety
Testing
with new
formulation

Phase IIa. NSD or
TD/Campy @ >2-5 g/day
or alternative formulation

STRATEGY FOR DEVELOPMENT OF PROVIR

(refer to diagrams, pp. 8 to 11)

Introduction: The critical information required to initiate phase Ila studies (page 8) will derive from a study in which SP-303 in H₂O (as opposed to NaHCO₃) will be tested in cholera toxin-treated mice. Results showing reduction of intestinal fluid would mean that the Ila studies can begin, whereas, lack of or poor activity would require the development of a new formulation to protect against the loss of biological activity due to acid lability of SP-303.

Contingency plan in case SP-303/H₂O is inactive in CI SAM/mouse model (page 9): This scenario would comprise a major set-back for the program in regard to timing, perhaps taking up to a year longer to get to the NDA. The proposal calls for development of a new formulation to protect against acid-caused inactivity of SP-303. The latter may include an enteric-coated capsule, higher dosages of a regular capsule, or giving SP-303 with an appropriate buffering or acid-reducing system. Subsequent animal tox studies may be required prior to human safety testing. Once the new formulation is developed and proven safe, open label (OL) studies at dosages >2-5 g/day are proposed late in using traveler's diarrhea (TD) and non specific diarrhea (NSD) as described in the paragraph below. Obviously, requirement of a new formulation would impact on the timing and the design of the protocol of the phase I MTD study (see contingency plan below).

Left-hand side flow chart (page 8): Since traveler's diarrhea (TD) and non specific diarrhea (NSD) are different diseases, this strategy assumes that SP-303 will be active against bacterially induced secretory diarrhea (TD) and NSD which is also believed to have a secretory component to its pathophysiology. Our preclinical studies predict activity against enterotoxigenic *E. coli* (ETEC) and other bacteria causing TD, but we have no evidence supporting activity against NSD for which an etiologic agent has never been identified. However, studies by DuPont et al., using antisecretory drugs, have demonstrated activity against both TD and NSD, which suggests the possibility that Provir will have activity against both diarrheal diseases.

Report No SP-303-E-074	SHAMAN PHARMACEUTICALS, INC.	Edition Date
Section PK/Metabolism	Effect of Enteric Coated SP-303 on Intestinal Fluid Accumulation in Cholera Toxin-treated Mice	Superseded Date Original Edition
Subsection	Final	Page 1 of 10

Abstract

This report summarizes the results of two experiments. The purpose of this study was to determine the effect of enteric-coated SP-303 on fluid accumulation in the intestinal tract of mice treated with cholera toxin (CT). Inhibition of fluid accumulation in this model by a test compound indicates the potential of the compound as an antidiarrheal agent. At initial time (t_0), mice were orally dosed with CT (15 μ g per average body weight of ~ 20 g) and anorectally sealed with a cyano-acrylamide ester. Three hours later (t_3 h), a single dose suspension of enteric coated SP-303 (131 mg SP-303/kg) in 0.75% gum guar (vehicle) was administered by oral gavage. Water and control solutions consisting of equivalent concentration of Eudragit and sugar in vehicle were also administered to two control groups. After 6 or 7 hour (t_6 and t_7 h) incubation of CT, mice were sacrificed and the entire murine small intestine tissue from the pylorus to the rectum including cecum was isolated. Fluid accumulation (FA) was measured as the ratio of the mass of accumulated fluid in the small intestine and rectum including cecum versus the mass of the small intestine minus the mass of the fluid. Under the experiment conditions, enteric coated SP-303 was shown to significantly reduce fluid accumulation in the small intestine of sealed adult mice treated with CT. In the second experiment, oral enteric coated SP-303 was capable of reducing the FA ratio by an average of 45% and 38% compared to the mean FA ratio in water controls and Eudragit/sugar/vehicle controls, respectively, at a concentration of 131 mg SP-303/kg.

1. INTRODUCTION

SP-303 is an oligomeric proanthocyanidin isolated from the South American tree *Croton lechleri*. The compound is currently being evaluated in preclinical trials as an antidiarrheal drug candidate. SP-303 previously exhibited activity in the cholera toxin/mouse model when it was administered orally in a solution of 7% NaHCO₃ (Reports # SP303-E-069 and SP303-E-070). By contrast, when the compound is dosed in an aqueous vehicle, it is not active. These findings, combined with the known liability of the compound at acidic pH values (in-house unpublished data), suggest that it is necessary to protect SP-303 from the acidic environment of the stomach (pH ~1.5) to obtain activity. Thus, SP-303 was manufactured as enteric coated beads which are designed to resist dissolution at acidic pH. However, once in the neutral to slightly basic pH environment of the small intestine, the enteric coating readily dissolves and releases SP-303. Therefore, the purpose of the studies described in this report were to determine if enteric coated SP-303 would be active in the cholera toxin/mouse model.

Eudragit is an acrylic polymer frequently used in the coating of solid dosage forms. Eudragit films are insoluble below pH 5 and thus resistant to gastric fluid. The Eudragit film dissolves at pH values above 5.5, and thus dissolves in the neutral to weakly alkaline medium of the intestinal

SHAMAN PHARMACEUTICALS - CONFIDENTIAL INFORMATION

Report No	SHAMAN PHARMACEUTICALS, INC.	Edition Date
Section PK/Metabolism	Effect of Enteric Coated SP-303 on Intestinal Fluid Accumulation in Cholera Toxin-treated Mice	Superseded Date Original Edition
Subsection	Final	Page 2 of 10

fluid. Enteric coated SP-303 beads were prepared by PMRS (Pharmaceutical Manufacturing Research Services) for testing in the CT mouse model.

2. PURPOSE

The purpose of these experiments was to determine the effect of enteric-coated SP-303 on fluid accumulation in the intestinal tract of mice treated with cholera toxin (CT/mouse model).

3. CHEMICALS AND EQUIPMENT

3.1. Materials

The following materials were obtained from commercial suppliers: cholera toxin (List Biological Lab, lot # CVX-48-3D); cyano-acrylamide ester (Borden Inc., Columbus, OH); animal feeding needles (Popper and Sons, Hyde Park, NY); sodium bicarbonate (ACROS lot # 83559/1); gum guar (Sigma, lot # 94H0195); enteric coated SP-303 (PMRS, lot # R10574); Eudragit L30D (PMRS, lot # R10538); 40-60 mesh sugar spheres (PMRS, lot # R10542).

3.2. Preparation of CT Stock and Dosing Solutions

One ml of HPLC grade water (Mill Q) was added to one List Biological vial containing 1 mg of CT prior to dosing animals. Two different vials were pooled and stored at 4° C. CT dosing solutions were freshly prepared by diluting 240 µl of CT stock solutions with 560 µl of 7% NaHCO₃. Final concentration of NaHCO₃ was 4.9%. Each mouse received 15 µg of CT in 50 µl volume by oral gavage at initial time (t₀).

3.3. Preparation of SP-303 Enteric Coated Beads

3.3.1. SP-303 layering and Enteric Coating Components

The formulation for enteric coated SP-303 beads contains 17.3% (w/w) of nonpareil seeds (sugar spheres, 46/60 mesh) (Paulaur, lot # 60084060), 64.5% SP-303 (Shaman, lot # PL-097), 1.5% hydroxypropyl methylcellulose (HPMC, Dow Chemical Co., lot # MM9410162E), 0.5% Opadry Clear (Colorcon, lot # S835563), 14.5% Eudragit L30D (Rohm Tech., lot # 1250514132), 1.45% triethyl citrate (Morflex, lot # N5X291), glyceryl monostearate (Rohmn Tech, lot # 502-229), and purified water (USP).

3.3.2. SP-303 layering and Enteric Coating Process

Report No	SHAMAN PHARMACEUTICALS, INC.	Edition Date
Section PK/Metabolism	Effect of Enteric Coated SP-303 on Intestinal Fluid Accumulation in Cholera Toxin-treated Mice	Superseded Date Original Edition
Subsection	Final	Page 3 of 10

The SP-303 layering coating solution was prepared by adding HPMC and SP-303 to purified water, USP. The SP-303 solution was then mixed well until it was dissolved. The nonpareil seeds were loaded into the product bowl of the fluid bed processor (Niro-Precision Coater). The SP-303/HPMC solution was then layered on the nonpareil seeds by spraying the solution onto the fluidized nonpareil seeds. A target bed temperature was maintained at 30-35° C. SP-303 layering process was continued until all the solution has been applied. Once the SP-303 layering has been completed, a seal coat using Opadry Clear (prepared by mixing the Opadry Clear with Purified Water, USP) was applied. The target bed temperature was maintained at 30-35° C. When the seal coat has been applied, the pellets were discharged and screened through a 1000 µ and 425 µ screens. The layered spheres of which size is larger than 425 µ and smaller than 1000 µ were charged back into fluid bed processor. Meanwhile, the enteric coating solution was prepared by adding triethyl citrate and glyceryl monostearate to water that has been heated to 65° C with continued mixing. This solution was added to the Eudragit L30D-55 while mixing. The resulting enteric coating solution was then sprayed onto the layered spheres in the fluidized bed processor. The bed temperature was maintained at 30-35° C until all enteric coating solution was layered on the beads.

3.4. Preparation of Dosing Solution

To facilitate oral gavage and prevent instantaneous settling of the beads, a thickening agent, gum guar was used. One hundred ml of 0.75% guar gum was prepared and adjusted to pH 2 with 2 ml of 0.5 M HCl. Enteric coated SP-303 beads were suspended in 0.75% gum guar solution. Control solution consisting of equivalent final concentrations of Eudragit and sugar was also prepared in 0.75% gum guar solution.

4. METHODS

The experiments were performed according to Gabriel et al. (Reports # SP303-E-069 and SP303-E-070). 50- to 52-day-old male mice with body masses that ranged from 15.7 to 18.7 g were used. Test animals were wild type C57Bl/6 and were obtained from Charles River Lab. All animals were maintained in metabolism cages with water *ad libidum* for the duration of the experiment. Mice were fasted for 24 hours prior to start of the experiment and were deprived of food during the course of experimentation. Initially (t₀ h), mice were orally dosed with CT (15µg) and anorectally sealed with a cyano-acrylamide ester (Superglue). Three hours later (t₃ h), mice were orally dosed with a suspension of enteric coated SP-303 in gum guar solution. After a 6 (t₆ h) or 7 hour (t₇ h) incubation of CT, mice were sacrificed and the entire murine

Report No	SHAMAN PHARMACEUTICALS, INC.	Edition Date
Section PK/Metabolism	Effect of Enteric Coated SP-303 on Intestinal Fluid Accumulation in Cholera Toxin-treated Mice	superseceda Date Original Edition
Subsection	Final	Page 5 of 10

equivalent concentration of Eudragit and sugar (1.33 mg of Eudragit plus 1.046 mg of sugar per kg body weight). The vehicle consisted of acidified 0.75% gum guar solution. All animals were sacrificed at t_6 .

6.2. Experiment II

Experiment II was carried out on A total of 24 mice (8 mice per each treatment) were used in this study as follows:

Group A: mice were gavaged with CT at t_0 followed by a single dose of H₂O at t_3 and sacrificed at t_7 after CT dosing.

Group B: mice were gavaged with CT at t_0 . At t_3 , the mice received a single dose of enteric coated SP-303 (131 mg SP-303/kg body weight). The vehicle consisted of acidified 0.75% gum guar solution. All animals were sacrificed at t_7 .

Group C: mice were gavaged with CT at t_0 . At t_3 , the mice received a single dose of equivalent concentration of Eudragit and sugar (1.33 mg of Eudragit plus 1.046 mg of sugar per kg body weight). The vehicle consisted of acidified 0.75% gum guar solution. All animals were sacrificed at t_7 .

7. RESULTS AND DISCUSSION

7.1. Experiment I

Table 1 and Figure 1 show the effect of enteric coated SP-303 beads on inhibition of CT-induced fluid secretion in the sealed adult mouse model. SP-303 significantly ($p < 0.05$) reduced CT-induced fluid accumulation following oral single dose administration of 131 mg/kg after a seven hour incubation with cholera toxin (group C). Compared to the control group that was treated with water (group A), and the second control group that received Eudragit plus sugar (group E), group C (SP-303 coated beads in vehicle) significantly reduced the ratios of fluid accumulation by an average of 32% and 29%, respectively. Despite a smaller FA ratio for group C vs. group D (gum guar vehicle only), no statistical significance was found between both groups. Furthermore, when the total CT incubation time was only 6 h (not 7 h as for group C), enteric coated SP-303 in vehicle did not reduce fluid accumulation in the intestine (group B). The stomach of several mice in group B was opened at t_6 and visually examined. A significant number of the dosed SP-303 enteric coated beads in gum guar solution was found in the stomach. This might explain the higher FA ratio

Report No	SHAMAN PHARMACEUTICALS, INC.	Edition Date
Section PK/Metabolism	Effect of Enteric Coated SP-303 on Intestinal Fluid Accumulation in Cholera Toxin-treated Mice	Superseded Date Original Edition
Subsection	Final	Page 6 of 10

found in this group.

As a result of the difficulties encountered in oral gavaging the enteric coated beads, one mouse from group B and C died. Additionally, for unknown reasons, one mouse in group A (water only) died following gavage administration.

Table 1. The effect of enteric coated SP-303 beads on intestinal fluid accumulation in CT-treated mice

Group	No. of Mice	Treatment	Evaluation Time (h)	Fluid Accumulation* (mg fluid / mg intestine)
A	4	H ₂ O	6	1.49 ± 0.09 a
B	4	131 mg coated SP- 303 in gum guar /kg	6	1.56 ± 0.12 a
C	4	131 mg coated SP- 303 in gum guar /kg	7	1.02 ± 0.10 b
D	5	0.75% gum guar	6	1.18 ± 0.08 b
E	5	Eudragit & sugar/ gum guar	6	1.44 ± 0.11 a

* Means not sharing letter in common, differ significantly ($p < 0.05$) by Duncan's Multiple Range Test.

Report No	SHAMAN PHARMACEUTICALS, INC.	Edition Date
Section PK/Metabolism	Effect of Enteric Coated SP-303 on Intestinal Fluid Accumulation in Cholera Toxin-treated Mice	Superseded Date Original Edition
Subsection	Final	Page 7 of 10




Figure 1. Effect of enteric coated SP-303 beads on intestinal fluid accumulation in CT-treated mice. Groups A, B, C, D, and E are explained in Table 1 as well as in the text.

6.2. Experiment II

Based on the results obtained in experiment I which indicated the need for longer incubation time to assure complete transfer of the coated beads into the intestine, all animals in experiment II were sacrificed at t_7 after CT dosing. To achieve more reliable results, the number of animals was increased to 8 mice for each group. Table 2 and Figure 2 show the effect of enteric coated SP-303 on CT-induced fluid secretion in the sealed adult mouse model (experiment II). As could be seen, a single dose of 131 mg SP-303/kg significantly ($P < 0.05$) reduced CT-induced fluid accumulation after a seven hour incubation with cholera toxin. Compared to the control groups, A and C, SP-303 enteric coated beads (group B) significantly reduced the ratios of fluid accumulation by an average of 45% and 38%, respectively.

No mouse died as a result of oral gavage administration.

Report No	SHAMAN PHARMACEUTICALS, INC.	Edition Date
Section PK/Metabolism	Effect of Enteric Coated SP-303 on Intestinal Fluid Accumulation in Cholera Toxin-treated Mice	Superseded Date Original Edition
Subsection	Final	Page 8 of 10

Table 2. The effect of enteric coated SP-303 beads on intestinal fluid accumulation in CT-treated mice

Group	No. of Mice	Treatment	Fluid Accumulation* (mg fluid / mg intestine)
A	8	H ₂ O	1.28 ± 0.09 a
B	8	131mg SP-303 in gum guar solution/kg	0.71 ± 0.17 b
C	8	Eudragit & sugar/gum guar solution	1.15 ± 0.16 a

* Means not sharing letter in common differ significantly ($p < 0.05$) by Duncan's Multiple Range Test.




Figure 2. Effect of enteric coated SP-303 beads on intestinal fluid accumulation in CT-treated mice. Groups A, B, and C are explained in Table 2 as well as in the text.

Report No	SHAMAN PHARMACEUTICALS, INC.	Edition Date
Section PK/Metabolism	Effect of Enteric Coated SP-303 on Intestinal Fluid Accumulation in Cholera Toxin-treated Mice	Superseded Date Original Edition
Subsection	Final	Page 9 of 10

7. CONCLUSIONS

Under the experimental conditions, enteric coated SP-303 was shown to significantly reduce fluid accumulation in the small intestine of sealed adult mice treated with CT. Based on experiment II, oral enteric coated SP-303 (131 mg SP-303/kg) was capable of reducing the FA ratio by an average of 38%, compared to the mean FA ratio in Eudragit plus sugar controls. These results further support SP-303 as a potential antidiarrheal agent.

Report No	SHAMAN PHARMACEUTICALS, INC.	Edition Date
Section PK/Metabolism	Effect of Enteric Coated SP-303 on Intestinal Fluid Accumulation in Cholera Toxin-treated Mice	Superseded Date Original Edition
Subsection	Final	Page 10 of 10

8. SIGNATURES

Prepared by: _____ Date _____
Adam Sabouni, Group Leader

Prepared by: _____ Date _____
Mei-Fong King, Scientist

NOTEBOOK NO. 333

ISSUED TO Mei-Fong King

ON _____

DEPARTMENT PK/Metabolism

RETURNED _____

microfilmed

PK # 2103

—SCIENTIFIC NOTEBOOK CO.—
2831 LAWRENCE AVE.
P.O. BOX 238
STEVENSVILLE, MI 49127
616-429-8285



PKA/Statistics

ENTERIC COATED SP-200 ON INTESTINAL FLUID ACCUMULATION IN GT-TREATED MICE					
EXPERIMENT 7					
Measure ID	A	B	C	D	E
	MSD	Coated SP-200 / 3 h	Coated SP-200 / 4 h	0.75% Quip/Quip	Enteric/Enteric/Quip
1	1.47	1.42	0.87	1.18	1.27
2	1.74	1.79	0.84	1.32	1.29
3	1.32	1.73	1.21	0.88	1.37
4	1.42	1.29		1.27	1.38
5			0.84	1.21	1.80
Mean	1.49	1.65	1.02	1.18	1.44
STD	0.18	0.24	0.29	0.18	0.24
SE	0.09	0.12	0.19	0.09	0.11
Analysis: Single-Factor					
Summary					
Group	Count	Sum	Average	Stdev	Variance
Column 1	4	5.948904299	1.487226074	0.032264845	
Column 2	4	6.23225422	1.55813855	0.057873823	
Column 3	4	4.061855848	1.015463962	0.038603967	
Column 4	3	3.598127594	1.199375865	0.028717749	
Column 5	5	7.207682468	1.441536493	0.059589878	
ANOVA					
Source of Variation	SS	df	MS	F	P-value
Between Groups	0.890773708	4	0.222693427	5.096672853	0.00894497
Within Groups	0.734458953	17	0.043203483		2.98471114
Total	1.615232661	21			
B vs. D					
t-Test: Two-Sample Assuming Equal Variances					
Variable 1	Variable 2	Mean	Mean	Variable 1	Variable 2
Mean	1.55813855	1.178025811	Mean	1.015463962	1.178025811
Variance	0.037873823	0.028717749	Variance	0.038603967	0.028717749
Observations	4	5	Observations	4	5
Pooled Variance	0.040070388		Pooled Variance	0.032240414	
Hypothesized Mean	0		Hypothesized Mean	0	
df	7		df	7	
t	2.635735819		t	-1.348600187	
P(T<=t) one-tail	0.012388068		P(T<=t) one-tail	0.108278801	
t Critical one-tail	1.894577508		t Critical one-tail	1.894577508	
P(T<=t) two-tail	0.024776136		P(T<=t) two-tail	0.216557602	
t Critical two-tail	2.36462258		t Critical two-tail	2.36462258	
C vs. E					
t-Test: Two-Sample Assuming Equal Variances					
Variable 1	Variable 2	Mean	Mean	Variable 1	Variable 2
Mean	1.015463962	1.441536493	Mean	1.015463962	1.441536493
Variance	0.038603967	0.059589878	Variance	0.038603967	0.032264845
Observations	4	5	Observations	4	4
Pooled Variance	0.051024544		Pooled Variance	0.035934406	
Hypothesized Mean	0		Hypothesized Mean	0	
df	7		df	8	
t	-2.811778638		t	-3.513787868	
P(T<=t) one-tail	0.013038298		P(T<=t) one-tail	0.004291498	
t Critical one-tail	1.894577508		t Critical one-tail	1.943180903	
P(T<=t) two-tail	0.026076596		P(T<=t) two-tail	0.012582997	
t Critical two-tail	2.36462258		t Critical two-tail	2.447913841	

Reviewed & Understood by me,

Date

Invented by

Date


Robert Duen

Recorded by *Mei-Fong King*



PK/Metabolism

EXPERIMENT 7.
EFFECT OF ENTERIC COATED SP-303 ON FLUID
ACCUMULATION IN CHOLERA TOXIN-TREATED MICE



Group	No. of Mice	t ₀ hr	t ₃ hr
A	4	CT/NaHCO ₃	H ₂ O
B	4	CT/NaHCO ₃	131mg/kg SP-303
C	4	CT/NaHCO ₃	*131mg/kg SP-303
D	5	CT/NaHCO ₃	0.75% Guar Gum
E	5	CT/NaHCO ₃	Eudragit & Sugar / Gum

* Mice were euthanized at 7 hours after CT dosing.

To Page

Witnessed & Understood by me,

Date

Invented by

Date

Recorded by Mei Fong Kine



NOTEBOOK NO. 368

ISSUED TO Mei Fang King

ON _____


DEPARTMENT Pharmacokinetics

RETURNED _____

microfilmed

job- # 210.3

—SCIENTIFIC NOTEBOOK CO.—
2831 LAWRENCE AVE.
P.O. BOX 238
STEVENSVILLE, MI 49127
616-429-8285



Exp. 8 - Effect of enteric coated SP-303
on fluid accumulation in CT-treated mice

Project No. _____
Book No. 368 TITLE

Page No. Notebook # 333 page 188

Objective: To determine the effect of enteric coated SP-303 on fluid
accumulation in CT-treated mice.

>1 to repeat the experiment 7 using larger scale of mice.

Experimental: see Notebook # 333 page 165 & Birvir Project
Experiment date: _____

Results: _____

[illegible]

PKM:abp:lam

EFFECT OF ENTERIC COATED SP-303 ON INTESTINAL FLUID ACCUMULATION IN CT-TREATED MICE

EXPERIMENT							
Mouse #	Eutharize Mouse Wt. (g)	Drugs	Gut & Fluid (g)	Gut minus Fluid (g)	Length of Gut (mm)	Fluid (g)	Eutharize Fluid/Gut (g)
A1	17.9	H2O	2.21	0.88	385	1.23	1.26
A2	18.6	H2O	2.34	0.87	385	1.47	1.69
A3	18.1	H2O	1.89	0.83	415	1.18	1.40
A4	17.1	H2O	1.82	0.88	420	0.84	0.88
A5	18.8	H2O	2.05	0.84	390	1.12	1.19
A6	18.7	H2O	2.08	0.82	415	1.26	1.53
A7	18.0	H2O	2.02	0.86	430	1.08	1.11
A8	18.6	H2O	1.83	0.82	380	1.01	1.24
MEAN	17.7		2.04	0.89	404	1.14	1.28
STD	0.8		0.18	0.07	18	0.19	0.28
SE	0.3		0.08	0.03	7	0.07	0.09
Mouse #	Mouse Wt. (g)	Drugs	Gut & Fluid (g)	Gut minus Fluid (g)	Length of Gut (mm)	Fluid (g)	Fluid/Gut (g)
B1	17.0	Coated SP-303	1.28	0.95	420	0.32	0.34
B2	18.5	Coated SP-303	1.60	0.93	400	0.68	0.73
B3	17.3	Coated SP-303	1.64	0.65	400	0.99	1.52
B4	16.6	Coated SP-303	1.21	0.95	370	0.27	0.28
B5	18.9	Coated SP-303	1.37	1.11	435	0.26	0.24
B6	16.3	Coated SP-303	1.68	0.86	410	1.00	1.18
B7	18.1	Coated SP-303	1.47	1.06	435	0.41	0.39
B8	18.4	Coated SP-303	1.62	0.79	365	0.83	1.04
MEAN	17.4		1.61	0.81	404	0.58	0.71
STD	1.0		0.21	0.18	27	0.32	0.48
SE	0.3		0.08	0.05	9	0.11	0.17
Mouse #	Mouse Wt. (g)	Drugs	Gut & Fluid (g)	Gut minus Fluid (g)	Length of Gut (mm)	Fluid (g)	Fluid/Gut (g)
C1	17.9	Eudragit/Sugar/Gum	2.03	0.98	415	1.07	1.11
C2	17.4	Eudragit/Sugar/Gum	1.65	0.63	405	1.01	1.60
C3	18.4	Eudragit/Sugar/Gum	1.02	0.82	400	0.19	0.24
C4	17.3	Eudragit/Sugar/Gum	1.87	0.88	390	1.00	1.14
C5	18.7	Eudragit/Sugar/Gum	1.78	0.91	405	0.85	0.84
C6	16.7	Eudragit/Sugar/Gum	2.07	0.98	410	1.11	1.18
C7	17.2	Eudragit/Sugar/Gum	2.12	0.95	400	1.17	1.24
C8	17.8	Eudragit/Sugar/Gum	2.18	0.79	385	1.40	1.78
MEAN	17.6		1.94	0.86	401	0.98	1.18
STD	0.7		0.38	0.11	18	0.35	0.48
SE	0.2		0.13	0.04	4	0.13	0.16

MFK

Witnessed & Understood by me,

Robert L. Lacey

Date

Invented by

Date

Recorded by Mei-Fong King

To

EXPERIMENTAL LOCATION OF THE ON INTERNAL FLAME ACCUMULATION IN C-THEATER

[illegible]


To Page No. 1

Used & Understood by me,

Date**Invented by****Date**

PK/Metabolism

EXPERIMENT 8.
EFFECT OF ENTERIC COATED SP-303 ON FLUID
ACCUMULATION IN CHOLERA TOXIN-TREATED MICE



Group	No. of Mice	t ₀ hr	t ₃ hr	Fluid Accumulation (mg fluid / mg intestine)
A	8	CT/NaHCO ₃	H ₂ O	1.28 A*
B	8	CT/NaHCO ₃	131mg/kg SP-303	0.71 B*
C	8	CT/NaHCO ₃	Eudragit & Sugar / Gum	1.15 A*

* Means not sharing letter in common differ significantly by Duncan's Multiple Range Test.

Witnessed & Understood by me,

Date

Invented by

Date

R. D. J. [Signature]

Recorded by Mei-Feng King

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.